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Abstract 
Background: In addition to evidence for a protective role of antibodies to the malaria blood stage antigen merozoite 
surface protein 1 (MSP1), MSP1 antibodies are also considered as a marker of past malaria exposure in sero-epidemio-
logical studies.
Methods: In order to better assess the potential use of MSP1 serology in malaria chemoprophylaxis trials in endemic 
areas, an analysis for the prevalence of antibodies to both Plasmodium falciparum and Plasmodium vivax MSP142 in 
healthy Cambodian adults was conducted at two sites as part of an active, observational cohort evaluating the effi-
cacy of dihydroartemisinin-piperaquine (DP) for uncomplicated malaria (ClinicalTrials.gov identifier NCT01280162).
Results: Rates of baseline sero-positivity were high (59 and 73 % for PfMSP142 and PvMSP142, respectively), and titers 
higher in those who lived in a higher transmission area, although there was little correlation in titers between the two 
species. Those volunteers who subsequently went on to develop malaria had higher baseline MSP142 titers than those 
who did not for both species. Titers to both antigens remained largely stable over the course of the 4–6 month study, 
except in those infected with P. falciparum who had multiple recurrences.
Conclusion: These findings illuminate the difficulties in using MSP142 serology as either a screening criterion and/or 
biomarker of exposure in chemoprophylaxis studies. Further work remains to identify useful markers of malarial infec-
tion and/or immunity.
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Background
As US armed forces continue to deploy to malaria 
endemic areas for both military and humanitarian mis-
sions, development of efficacious anti-malarial chemo-
prophylaxis with convenient regimens and minimal side 
effects remains a top priority for the Department of 
Defense [1]. Weekly mefloquine administration is asso-
ciated with well-described neuropsychiatric toxicity 
requiring mental health evaluation, and recently received 
a 2nd black box warning for this from the US Food and 
Drug Administration (FDA) [2, 3]. Currently favoured 
options include daily doxycycline, which may have lower 
compliance than mefloquine and considerable side 
effects, or atovaquone/proguanil, which is both expensive 
and susceptible to resistance [4].
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Historically, chemoprophylaxis agents have been 
licensed based on the results of placebo-controlled stud-
ies in semi-immune volunteers. However, this approach 
raises two ethical dilemmas—justification for the use of 
placebo and post-trial access for the study population 
[5]. Non-inferiority studies between active compara-
tor drugs is an alternative approach hampered by the 
logistical challenges and costs associated with very large 
sample sizes needed to compare products with 95  % or 
better efficacy. This was underscored in a trial compar-
ing weekly mefloquine with tafenoquine in Australian 
soldiers deployed to East Timor. While there were no 
cases of Plasmodium falciparum malaria in either treat-
ment arm, true efficacy could not be determined due to 
lack of a surrogate endpoint for malaria exposure [6], 
and required an estimate based on attack rates in nearby 
indigenous personnel [7]. Another key challenge is 
extrapolation of chemoprophylactic efficacy results from 
semi-immune populations living in endemic areas to 
non-immune travelers, a population who may be at great 
risk for more severe illness.
A surrogate biomarker for malaria exposure would 
ensure future active comparator trials are interpret-
able. Antibodies to blood stage malaria antigens, such 
a merozoite surface protein 1 (MSP1), have been evalu-
ated in sero-epidemiological surveys as estimates of 
malaria exposure [8, 9]. The serologic stability of MSP1 
make it an attractive candidate as a surrogate endpoint 
of exposure for chemoprophylaxis trials, but unfortu-
nately, in a proof-of-concept P. falciparum controlled 
human malaria infection (CHMI) study by Moon et al. 
[10], antibodies to PfMSP142 were not induced in 
malaria-naive, healthy volunteers taking mefloquine 
chemoprophylaxis with strict clinical and parasitologic 
monitoring; however, it may be possible that assessment 
MSP142 as a surrogate biomarker in endemic popula-
tions may be of more utility.
The US and Cambodian militaries have recently been 
working to develop new anti-malarial chemoprophylaxis 
agents [11]. Malaria in Cambodia is characterized by a 
low incidence of P. falciparum and Plasmodium vivax 
infections in roughly equal proportion, focal transmission 
by forest-dwelling Anopheles mosquitoes with sporadic 
infections, all occurring in the epicenter of anti-malar-
ial resistance [12–15]. Cambodian military personnel 
deploying from the non-endemic urban areas of Cambo-
dia to forested areas along the border may be essentially 
malaria-naïve and at risk. This investigation assessed 
MSP142 titers in a cohort of healthy asymptomatic Cam-
bodian soldiers in a malaria endemic area [16] in order to 
evaluate its utility as a biomarker for pre-existing immu-
nity as well as a surrogate endpoint of malaria exposure 
for future chemoprophylaxis studies.
Methods
Study design
Serum samples were isolated from 5  ml of periph-
eral blood drawn from volunteers enrolled in an IRB-
approved study conducted in Anlong Veng District, 
Oddor Meanchey Province, Cambodia. From September 
2010 until February 2011, a two-arm, randomized, open-
label trial of 2- versus 3-day treatment regimen of dihy-
droartemisin-piperaquine (DP) nested within an active 
observational cohort study was conducted as previously 
reported (ClinicalTrials.gov identifier NCT01280162) 
[16]. Briefly, 256 volunteers were recruited and screened 
from two sites in Anlong Veng District, designated Site A 
and Site B. The former was near a village along the forest 
fringe, while the latter was in a remote, densely forested 
area. Two hundred twenty-two volunteers were enrolled 
and followed until 80 volunteers (representing a 40  % 
cumulative attack rate over 4  months) became infected 
with uncomplicated P. falciparum or P. vivax malaria and 
were treated with 2 or 3 days of DP. Blood was drawn for 
antibody titers at screening/enrollment, time of malaria 
infection, 42  days after completion of DP therapy, and 
any time of malaria recurrence. Recurrent cases were dis-
tinguished as recrudescence or reinfection by genotyping 
for MSP-1, MSP-2, and GLURP (glutamate-rich protein) 
allelic variants as previously described [17]. Genotyping 
for P. vivax recurrences was not performed.
Antigens
The 3D7 allele of the 42-kDa recombinant protein, P. 
falciparum merozoite surface protein-1 (MSP-142), was 
provided by Dr. Evelina Angov, manufactured at WRAIR 
as described in [18]. This is an E. coli expressed, recom-
binant protein with 391 amino acids, of which 17 are 
non-MSP-142 amino acids fused to the N-terminus (bp 
4087–5208, GenBank accession number Z35327, encod-
ing amino acids 1362–1736).
Plasmodium vivax merozoite surface protein-1 (MSP-
142), was provided by Dr. Sheetij Dutta, WRAIR, and is 
also an E. coli expressed, recombinant protein based on 
the P. vivax Sal I allele, 380 amino acids long, consisting 
of 18 non-MSP-142 amino acids fused to the N-terminus 
part of MSP-142 (amino acids 1350–1789) [19]. Also 
assessed in preliminary enzyme-linked immunosorbent 
assay (ELISA) comparisons of titers were the CAMP and 
FVO alleles of P. falciparum MSP-142, kindly provided by 
Dr. Evelina Angov.
ELISA methods
Plates were coated with 100 µl PfMSP142 and PvMSP142 
at 1  µg/ml and allowed to incubate overnight at 4  °C. 
Plates were washed four times and blocked with 3  % 
bovine serum albumin-phosphate buffered saline with 
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Tween 20 (BSA-PBST) for 1 h; the samples were loaded 
at serial twofold dilution. After 2 h incubation at 37  °C, 
plates were washed four times and incubated for 2  h at 
37  °C with peroxidase-conjugated anti-human IgG(γ) 
(KPL, Inc., Gaithersburg, MD, USA) at 1:8000. The plates 
were washed four times and incubated with ABTS sub-
strate (KPL, Inc., Gaithersburg, MD, USA) for 30 min at 
room temperature. The reaction was stopped with stop 
solution (KPL, Inc., Gaithersburg, MD, USA) and plates 
read on an automatic plate reader Spectromax340PC. 
The absorbance at 405 nm was determined for each well 
with the resulting data applied to a four parameter logis-
tic curve using Softmax Pro Version 5.2 software (Molec-
ular Devices Corporation, CA, USA). The serum dilution 
required to yield an optical density of 1.0 was defined as 
the titer. Positive controls consisted of plasma samples 
from highly reactive sera. Negative controls consisted of 
pooled plasma from individuals from Thailand obtained 
through the Thai Red Cross. Before running all study 
samples, 10 random serum samples were selected to 
compare ELISA titers among the three main haplotypes 
of PfMSP142 (CAMP, FVO and 3D7). The titers were sim-
ilar among the three alleles (data not shown), suggesting 
strong serologic cross-reactivity in this small sample sub-
set from Cambodia. Thus the Pf3D7 allele was selected 
for all study ELISAs.
MSP1 42‑kDa region genotyping (PCR and sequencing)
Genotyping of PfMSP1 42-kDa region was determined by 
using semi-nested PCR, and PfMSP119 then sequenced 
to determine allelic haplotype. Primer sequences (Prima 
Scientific Co., Ltd.,) were as described previously [20]. 
The PCR products from the primary PCR, 1124 and 
1072  bp for MAD20 or K1, respectively, were used as 
template for amplifying PfMSP119 which yielded 435 
and 426 bp of PCR product, respectively. Genomic DNA 
was extracted by using MagNA Pure compact instru-
ment (Roche Diagnostics Ltd., Rotkreuz, Switzerland) 
according to manufacturer’s instruction. The primary 
and secondary PCR reactions were carried out in 25  µl 
reaction volume on Peltier Thermal Cycler (MJ Research, 
Waltham, MA, USA). Master Mix of both PCRs was com-
prised of 1× PCR buffer with MgCl2 (Qiagen®, Valencia, 
CA, USA), 0.1 µM of primers, 0.2 mM of dNTP (Roche 
Applied Science, Germany) 0.1  U/µl of Taq polymer-
ase (Qiagen® Valencia, CA, USA), and extracted DNA 
(adjusted concentration to 3 ng/µl). PCR conditions were 
as follows: pre-denaturation at 94  °C for 1 min followed 
by 40 cycles (35 cycles for secondary PCR) of denatura-
tion at 94 °C for 45 s, annealing at 53 °C for 45 s (55 °C for 
secondary PCR), extension at 60  °C for 5 min. The PCR 
products were loaded on 1  % agarose gel, stained with 
ethidium bromide, and visualized under UV illumination 
(VersaDoc®, BIORAD, Hercules, CA, USA). For the sec-
ondary PCR, PfMSP119 variants; E/TSR/L, E/TSG/L, E/
KNG/F, and Q/KNG/L with GenBank accession number 
HM569746, HM569747, HM569748, and HM569750, 
respectively, were used as reference strains in sequence 
alignment. PCR products were purified by using a PCR 
purification kit (Qiagen®, Valencia, CA, USA) prior to 
sequencing. Sequencing was performed at AIT Biotech, 
Pte, Ltd., (Singapore) and was analysed and aligned by 
using BioEdit Sequence Alignment Editor Software (ver-
sion 7.2.5).
Statistical analysis
Prism v 6.0 was used for statistical analyses. The geo-
metric mean antibody titer at each time point was deter-
mined with 95 % confidence intervals. Negative controls 
were determined by ELISA analysis of serum samples 
from ten non-malaria infected healthy Thai adults living 
in Bangkok. The geomean titer of negative controls for P. 
falciparum MSP1 was 225 units and for P. vivax MSP1, 
379 units. Cut-off for seropositivity was defined as >3 
standard deviations (SDs) above the geomean, or 360 
and 494 units for P. falciparum and P. vivax, respectively. 
Comparison of numbers of volunteers seropositive or 
seronegative was performed by using Fishers exact tests 
with two-tailed p values. To compare level of titers, the 
data was log transformed to obtain normal distribution 
and the geomean titers reported. Titers were compared 
either using unpaired t tests or one-way ANOVA with 
Tukeys post-test comparisons and comparisons between 
vivax and falciparum titers done using Pearson’s corre-
lation coefficient. The multiple regression analysis was 
conducted separately using SAS v 9.2.
Results
Titers and sero‑positivity to Plasmodium falciparum 
and Plasmodium vivax MSP142 in adults in northern 
Cambodia
A total of 256 adults were screened for the study with 
serum samples obtained from all but one. Geomet-
ric mean titers and (range) for PfMSP142 were 904 
units (16–669,774) and for PvMSP142 were 2207 units 
(65–965,671). Malaria transmission in Cambodia is sea-
sonal, with transmission increasing during the rainy 
season from May to October, with peaks in Septem-
ber and November [21]. The majority of malaria nega-
tive volunteers, 84  % (179 of 214), were screened and 
enrolled during the first month of the study in September 
through October with a second enrollment period start-
ing in late November to replace drop-outs [35 volunteers 
(16  %)]. There were 41 volunteers who were found to 
have malaria at screening and began treatment imme-
diately. Of these, all nine patients with P. falciparum or 
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mixed P. falciparum/P. vivax malaria were seroposi-
tive for PfMSP142 with a geomean titer of 12,300 units, 
nearly 15× higher than those who did not have P. falci-
parum (822 units, unpaired t test, p  <  0.0001). There 
were 32 of 41 patients with P. vivax malaria, and 88  % 
were seropositive for PvMSP142, with geomean titer 4242 
units, roughly 2× higher than those without P. vivax 
(2010 units, unpaired t test, p = 0.038). Among the 214 
volunteers negative for malaria at enrollment, preexist-
ing exposure based on serology was uneven at the two 
study sites—Site A, neighboring a small village and Site 
B, in a forested area (Fig. 1a). Site B had higher geomean 
titers for PfMSP142 (1258 vs 571 units; unpaired t test, 
p  =  0.0037) and mean PvMSP142 titers of 3637 versus 
1076 units, respectively (unpaired t test, p < 0.0001).
When timing of malaria episodes was grouped into 
<12  months ago, more than 12  months ago and never 
(Fig.  1b), P. falciparum and P. vivax MSP1 titers in site 
A were significantly higher in those with malaria within 
12 months than for those not having malaria within the 
past year or never, p =  0.0117 and p =  0.0057, respec-
tively (one-way ANOVA with Tukeys post-test). At site B, 
titers to both antigens were not different among the three 
groupings of malaria timings: PfMSP1 (p = 0.7734) and 
PvMSP1 (p = 0.1777, one-way ANOVA).
For malaria negative volunteers at enrollment, Site B 
participants were more often seropositive to PfMSP142: 
70/101 or 69 %, compared to Site A participants: 57/113 
or 50 % (p = 0.0036 Fishers exact test). The same was true 
for PvMSP142 with 88/101 (87  %) seropositive at site B 
versus 69/113 (61 %) at site A (p < 0.0001, Fishers exact 
test). Seropositivity rates per last reported malaria epi-
sode (three groupings) are shown in Fig. 1b underneath 
titer ranges. At Site A, there was a trend in decreas-
ing number of seropositive volunteers with increasing 
time since last infection, while at Site B there was lit-
tle difference in rates of seropositivity and last recalled 
malaria episode. Despite giving a history of never having 
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Fig. 1 Titers to P. falciparum and P. vivax MSP142 by site and clinical history. Antibody titers to P. falciparum MSP142 (a, c) and Pv MSP142 (b, d) in 
smear-negative volunteers at screening. a, b Titers grouped according to site: site A (n = 113) versus site B (n = 101) while c, d show titers at each 
site according to time since most recent malaria infection (any species): within past year, more than 1 year ago and never. c, d Also include the 
percent of seropositive volunteers in each timing category and site. Black line is geomean titer for each site, while the blue line represents cutoff titer 
for seropositivity
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malaria, 40 and 45  % of volunteers from Site A were 
seropositive for PfMSP142 and PvMSP142, respectively, 
with even higher rates for Site B: 61 and 87  %. Titers 
for both MSP142 antigens were similar if the volunteer 
reported having malaria 1, 2, 3, or >3 times in the past 
year (PfMSP142 titers 840, 1960, 4526 and 852 units 
respectively, one-way ANOVA, p =  0.13 and PvMSP142 
titers 3912, 3157, 2108, 6437 units respectively, one way 
ANOVA, p = 0.65). Although nearly half (49 %) of volun-
teers were seropositive for both P. falciparum and P. vivax 
MSP1 at enrollment and only 17 % seronegative for both, 
there was only a weak correlation of titer levels between 
falciparum and vivax MSP142 at site A (r = 0.3262, Pear-
son correlation coefficient, p = 0.0004), and no correla-
tion at site B (r =  0.123, Pearson correlation coefficient 
p = 0.2216).
Titers at enrollment and subsequent malaria infection
Among181 malaria-negative volunteers enrolled, 50 sub-
sequently developed malaria within 8–114  days after 
enrollment: 37 P. vivax, 10 P. falciparum, two mixed 
P. falciparum/P. vivax, and one Plasmodium malariae 
cases. P. falciparum and P. vivax MSP142 titers of 49 
were assessed to evaluate the hypothesis that those with 
higher titers at enrollment would be protected against 
subsequent infection with malaria, possibly confound-
ing a chemoprophylaxis study conducted in an endemic 
area. For both antigens, titers at enrollment were high-
est in those who developed subsequent homologous 
infection (Fig.  2a, b). PfMSP142 titers at enrollment in 
those subsequently contracting P. falciparum malaria 
were 6445 units, more than 10× higher than those who 
never developed malaria, 608 units (n = 126), and higher 
than those who developed P. vivax infection, 993 units 
(n  =  37) (one-way ANOVA, p  =  0.0002, with Tukeys 
post-test). Similarly, the titers to PvMSP142 at enrollment 
were higher for those who subsequently contracted P. 
vivax malaria (6105 units) than those who never devel-
oped malaria (1158 units), or P. falciparum malaria (3235 
units) (one-way ANOVA p < 0.0001, Tukeys post-test).
When analysed using multiple regression model, 
adjusting for time to infection and site of enrollment, 
those with higher titers to PfMSP142 at enrollment were 
still more likely to develop subsequent P. falciparum 
malaria than those who remained malaria-free over the 
course of the study (p  =  0.0065). Likewise, volunteers 
subsequently developing P. vivax malaria had higher 
baseline PvMSP142 titers than those remaining malaria-
free (p = 0.0006). This positive association also held for 
seropositivity. Of the 74 PfMSP142 volunteers seroposi-
tive at enrollment, 12 % went on to develop P. falciparum 
malaria compared to 2  % of 62 seronegative volunteers 
(relative risk 7.54, 95 % CI 0.98–57.9) while 39 % percent 
of those PvMSP142 seropositive subsequently developed 
P. vivax malaria versus 1 % of those who were PvMSP142 
seronegative (relative risk 27.1, 95 % CI 3.8–193).
Since the ELISA assay plate antigen was the 3D7 
allele of PfMSP142, the relationship between 3D7 anti-
body titers at enrollment and the infecting P. falciparum 
42-kDa haplotype was examined. Protection by 3D7 
MSP142 antibodies against homologous P. falciparum 





















































Fig. 2 MSP142 titers at enrollment and malaria outcome. Antibody 
titers to P. falciparum MSP142 (a) and Pv MSP142 (b) in smear-negative 
volunteers at enrollment based on the species of the first malaria 
infection contracted during the study or if remaining malaria nega-
tive. For PfMSP1, among three groups one-way ANOVA p = 0.0012, 
with Tukey’s post-test significant for P. falciparum infection compared 
to both P. vivax infection and no malaria. PvMSP1 titers among three 
groups: one-way ANOVA p < 0.0001 with Tukey’s post-test only sig-
nificantly different between P. vivax titers and no malaria
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of the 33 P. falciparum isolates revealed no 3D7/MAD20 
alleles. The majority of isolates (26/33 or 79 %) were the 
42-kDa CAMP allele, comprised of the MAD20 33-kDa 
plus the EKNGL 19-kDa haplotypes, while a minority 
(21 %) bore the FVO allele, comprised of the K1 33-kDa 
plus the QKNGL 19-kDa haplotype [20, 22]. Of those 
who had two P. falciparum infections, only one volunteer 
(178) had a new second P. falciparum infection (versus 
recrudescence for others). This volunteer had an initial 
CAMP infection in October followed by FVO infec-
tion in January at the time of discharge. The P. falcipa-
rum MSP1 3D7 titers rose from 6120 to 293,896 units, 
the third highest measured of any volunteer, suggest-
ing recent exposure and induction of immune response 
toward the new parasite, albeit non-protective.
Do multiple malaria recurrences influence MSP1 titers?
To look more closely at how multiple malaria infections 
may affect titers, the titers of volunteers with one or more 
recurrences are plotted and organized by groups in Fig. 3. 
Group 1 had at least two homologous infections, initial 
P. falciparum infection with P. falciparum recurrence or 
initial P. vivax infection with P. vivax recurrence.  Group 
2 had initial P. falciparum infection followed by P. vivax, 
and Group 3 had initial P. vivax infection followed by P. 
falciparum. Titers to PfMSP142 remained relatively sta-
ble over the course of the study in those with recurrent 
mono-infections with the exception of volunteers with 
initial P. vivax infection then P. falciparum infection, in 
which titers increased substantially with the P. falcipa-
rum infection. The single volunteer (178) who developed 
a new second P. falciparum infection (vs recrudescence) 
also had increasing titers at the new P. falciparum infec-
tion. Mixed infections induced varying titers although 
the number of volunteers was small. PvMSP142 titers 
remained quite stable over time in all groups.
Change in titers at study period end
In Fig. 4, titers are graphed by groups according to spe-
cies of intervening malaria infection to assess if malaria 
infections could be detected by interval change in titers. 
For both PfMSP142 and PvMSP142, there was no statisti-
cally significant difference in titers between enrollment 
and discharge for any of the groups except for the four 
volunteers who developed multiple P. falciparum infec-
tions over the course of the study in whom the titers were 
much higher at discharge than enrollment (62,593 versus 
















































































































































































































































































Fig. 3 Longitudinal titers per species of infection and recurrence. a, c, e PfMSP titers (red); b, d, f: PvMSP1 titers (green). a Group 1 Pf titers in those 
seven volunteers with 2 or 3 P. falciparum or mixed P. falciparum/P. vivax infections; asterisk indicates the one volunteer with a new P. falciparum 
infection, not recrudescence. b Group 1 with 7 representative volunteers with P. vivax infections and P. vivax relapses only. c, d Titers in those with 
mono—P. falciparum  infection followed by mono—P. vivax infection. e, f Titers in volunteers with mono—P. vivax  infection followed by mono—P. 
falciparum  infection. Study period is divided into approximately 2 week blocks along X axis. Geometric symbols indicate a clinic visit with serology 
blood draw. Those symbols in black are ones with a positive malaria blood smear. All diagnoses are by PCR-corrected blood smears
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falciparum infections in this group of four patients, 10 
had a MSP1 19-kDa haplotype of EKNG. At discharge, 
titers for these subjects with multiple P. falciparum infec-
tions were higher than those who had never had malaria 
(457 units) as well as those who had one P. vivax infection 
(497 units) (p < 0.0001, one-way ANOVA, Tukeys post-
test) but not those who had one P. falciparum infection 
(3784 units). Titers to PvMSP142 did not differ signifi-
cantly among the groups (p = 0.1328, one-way ANOVA).
Discussion
The US military continues to develop new anti-malarial 
drugs and vaccines as part of its mission to protect the 
war fighter. Historically, anti-malarial chemoprophy-
laxis studies for licensure in Asia and elsewhere have 
used placebo-controlled study designs in semi-immune 
populations, with recent examples including tafenoquine 
in soldiers of the Royal Thai Army [22] and azithromy-
cin in Indonesian soldiers [23]. However, the declara-
tion of Helsinki 2000 raised serious concerns regarding 
placebo-controlled study designs where alternative 
effective therapies exist [5]. An established, validated 
biomarker for malaria infection would allow for calcu-
lation of protective efficacy in active-controlled malaria 
prevention studies. To this end, in 2009, Moon et al. [10] 
performed a CHMI study administering P. falciparum 
to healthy volunteers under mefloquine prophylaxis to 
assess seroconversion rates of P. falciparum MSP142, 
defined as a fourfold rise in titers. None of the volunteers 
seroconverted, and only four of six controls, those who 
did not receiving mefloquine who did develop malaria, 
seroconverted.
This study aimed to characterize background and 
changes in humoral P. falciparum and P. vivax MSP142 
responses during a single malaria season in order to 
gain insight to malaria exposure and immunity in a low 
transmission setting with multidrug resistant malaria in 
northern Cambodia and lay the groundwork for malaria 
prophylaxis studies. The predominantly resident military 
population was a mix of self-reported malaria-naïve and 
semi-immune individuals; some were newly arrived from 
non-transmission areas while other long-term veterans 
had likely had multiple exposures over several years while 
stationed in malarious areas. Transmission varied sub-
stantially between the two study locations, with signifi-
cantly higher attack rates during the cohort study at the 
forested site B compared to semi-urban site A [16]. Base-
line titers to P. falciparum and P. vivax MSP142 proteins 
in asymptomatic, aparasitemic adults varied greatly by 
individual, with a 1–5 log difference not directly attrib-
utable to geographic site nor reported clinical history of 
prior malaria infection. Geomean titers were higher in 
those reporting a malaria infection in the past year com-
pared to those with no history of disease, but significant 
overlap existed, underscoring the lack of utility of a single 
serological measurement as marker of immunity. Based 
on sero-positivity rates, prior exposure seemed quite evi-
dent, particularly for P. vivax, even in those reporting no 
clinical history of malaria.
The wide variation in baseline serology is similar to 
prior sero-epidemiology studies in both high and low 
transmission settings. Fowkes et al. [24] found that titers 
to merozoite surface antigens P. falciparum and P. vivax 
AMA1 could fluctuate widely in pregnant women liv-
ing in Thailand even when measured biweekly. Another 
study in northern Thailand found that in individuals with 
documented falciparum or vivax malaria infection in the 
past 6 years, only 48 % were sero-positive to PfMSP19 and 
11  % to P. vivax MSP119 [25]. Even in a hyperendemic 
transmission area in western Kenya, approximately 60 % 
of semi-immune children and adults surveyed did not 
have a humoral response to any of the three main allelic 
variants (CAMP, FVO and 3D7/MAD20) of PfMSP142 
[26]. This lack of correlation with reported malaria expo-
sure history raises significant doubts regarding the utility 
of MSP1 antibodies as an enrolment criterion for malaria 
prevention studies in even low transmission areas requir-
ing malaria-naïve volunteers. At best, aggregate seroprev-
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Fig. 4 Change in titers from enrollment to discharge. Antibody titers 
to PfMSP142 (a) and PvMSP142 (b) both at enrollment and discharge 
grouped by no malaria infection during the study, P. falciparum or P. 
vivax infection one time only and those with two or more P. falcipa-
rum or P. vivax infections
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prevention trials a priori and/or to interpret study results 
after the fact.
Volunteers who did not get malaria during the course of 
the cohort study had essentially no change in titer. Mean 
PfMSP1 titers hovered just above the upper limit of sero-
positivity at both time points suggesting this is the natural 
‘background’ titer of adults in rural Cambodia, although 
this would need to be validated during more than one 
transmission season. Ideally, sero-epidemiological stud-
ies conducted in areas with seasonal transmission would 
have humoral responses measured just before the onset of 
the transmission season. Since this study was nested in an 
active drug efficacy study, conducted several months after 
the rains had begun, baseline titer levels and rates of sero-
positivity may be overestimated. It is unclear if the high rate 
of sero-positivity signifies recent or remote infections, and 
it gives little indication of the number and species of prior 
infections, particularly for those with low titers. Regardless, 
the high rates did not appear to confer immunity.
Perhaps more importantly, there was little apparent 
‘booster effect’ of baseline titers in response to infection, 
except for PfMSP142 for the four volunteers with three 
malaria infections during the study period. The PfMSP1 
19-kDa haplotype for 10 of 11 infections for these four 
patients was EKNG; thus the higher titers do not rep-
resent a broadening of the immune responses by infec-
tion with different circulating haplotypes. With P. vivax 
infections, titers appeared either to wane or remain 
remarkably stable over time. As reported elsewhere, 
it is likely that the majority of P. vivax infections repre-
sented relapses [27], and this would suggest that relaps-
ing infection does not stimulate a significant rise in 
humoral response. A recent publication by Chuquiyauri 
et  al. [28] analysed antibody responses to P. vivax anti-
gens by microarray in Peruvian patients with P. vivax 
mono-infection and found that both height and breadth 
of responses were not different in those who were deter-
mined to have relapse versus P. vivax re-infection. More-
over, boosting may not be seen due to longer half-lives 
of MSP1 titers in low to medium transmission areas. 
Wipasa et al. [25] used a mixed-effects regression model 
analysis to estimate the half-life of MSP1 in northern 
Thai volunteers to be 7.6  years. These evidences, com-
bined with the data obtained here in northern Cambodia, 
strongly suggest MSP1 is unlikely to be a useful quanti-
tative serologic marker for malaria exposure during a 
chemoprophylaxis study.
Alternative biomarkers to other antigens, such as anti-
bodies to the circumsporozoite protein (CSP), which 
is located on the surface of the sporozoite, may be less 
affected by chemoprophylaxis. In an intervention-treat-
ment-vaccination (ITV) study in healthy Dutch volun-
teers, those taking chloroquine prophylaxis during three 
successive mosquito-borne P. falciparum infections were 
protected from subsequent P. falciparum challenge and 
seroconverted to CSP but not AMA1 or GLURP [29]. A 
study of Dutch soldiers under mefloquine prophylaxis 
while deployed to Zaire in 1994 showed 100  % efficacy 
while 11  % of soldiers had an increase in circumsporo-
zoite antibodies, suggesting malaria exposure [30]. Less 
is known about seroconversion with P. vivax malaria, 
although one study of deployed Thai soldiers found 
almost three-quarters contracted vivax malaria despite 
62  % being PvCSP seropositive at deployment; those 
who were seronegative did seroconvert with acute ill-
ness though the rise in titers was modest and fell quickly 
[31]. Thirty-eight percent of the Thai soldiers with docu-
mented, treated P. vivax malaria did not mount any CSP 
antibody response. There were not successive increases 
in CSP titers with relapses, a finding also demonstrated 
in Cambodian adults in this study, suggesting that a bio-
marker for P. vivax infection may be even more elusive. 
Whether pre-erythrocytic or erythrocytic, a single anti-
gen may not suffice as a biomarker; thus, adding immu-
nogenic antigens, such as MSP2 and schizont extract (SE) 
[32], or assessing the breadth of responses [33] plus newer 
bead arrays or microarrays [34, 35] may prove to be more 
useful, as biomarkers but these alternate approaches will 
need to be validated in chemoprophylaxis field studies.
In design of chemoprophylaxis studies in endemic 
areas, it is possible that innate immunity in semi-immune 
subjects may attenuate infection, thereby inflating the 
apparent protective efficacy of prophylactic drugs and 
overestimate their potential benefit to malaria-naïve indi-
viduals. The previous evidence for the protective role of 
P. falciparum and PvMSP1 in endemic areas has been 
mixed [36–39]. In this study, those with higher MPS1 
titers to either species at enrollment were more likely 
to develop malaria, and the proportion of volunteers 
remaining malaria-free was almost evenly split between 
those who were seropositive and seronegative, suggest-
ing these higher titers were more reflective of exposure 
than semi-immunity. No 3D7 haplotypes to the C-termi-
nus of MSP1 were detected, the region of MSP1 to which 
functional antibodies are thought to act, yet titers to this 
allelic haplotype were highly induced, perhaps merely 
reflecting cross-reactive immune response between three 
haplotypes 3D7, CAMP, FVO [20, 36]. Cross-reactivity 
may not translate to cross-protection, although this may 
depend on haplotype, as it has been shown that vaccina-
tion with the FVO allele of PfMSP142 induces a better 
homologous and heterologous antibody response than 
the 3D7 allele of MSP142 [40]. In addition, a traditional 
ELISA may not adequately capture function, as some 
antibodies have “blocking” activities and thus interfere 
with protective responses [41].
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Conclusion
Evidence for the establishment and duration of both 
serologic markers and functional malaria immunity in 
subjects living in Southeast Asia remain limited. Com-
pounding the complexities of assessment, unlike homolo-
gous laboratory strains used in challenge studies, malaria 
infections in endemic areas are frequently with heterolo-
gous strains or mixed species and responses reflecting the 
more complex transmission patterns such as observed in 
Cambodia. These factors combine to limit the current 
utility of serologic biomarkers of malaria immunity in 
malaria prevention studies. Studies to assess the develop-
ment of a broader array of serologic biomarkers in con-
trolled settings are needed.
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